We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
- Authors
Chen, Huey‐Ling; Lee, Chien‐Nan; Chang, Chin‐Hao; Lai, Ming‐Wei; Tsai, Ming‐Chieh; Mu, Shu‐Chi; Liu, Chun‐Jen; Shih, Jin‐Chung; Wen, Wan‐Hsin; Hu, Rui‐Ting; Huang, Chun‐Pin; Hu, Kuang‐Chun; Chen, Chie‐Pein; Lee, Chyi‐Long; Chien, Rong‐Nan; Chang, Kai‐Chi; Hsu, Hong‐Yuan; Lee, Chien‐Chang; Ni, Yen‐Hsuan; Chang, Mei‐Hwei
- Abstract
Background: The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation. Methods: The maternal and infant outcomes were compared in multi‐centre trials of high viral load HBsAg/HBeAg+ pregnant women receiving TAF or TDF from the third trimester until 2 weeks postpartum with intensive follow‐ups. To explore the dynamic pre‐ and postpartum changes in ALT levels, we used a group‐based trajectory model for analysing data of 332 women from three prospective studies. Results: After treatment, the maternal HBV DNA levels significantly decreased from baseline to delivery: 7.87 ± 0.59 to 3.99 ± 1.07 Log10 IU/mL TAF (n = 78) and 8.30 ± 0.36 to 4.47 ± 0.86 Log10 IU/mL (TDF, n = 53), with viral load reductions of 3.87 versus 3.83 Log10 IU/mL. The HBsAg‐positive rates among 12‐month‐old infants were 1.28% (1/78) versus 1.82% (1/55) respectively (p = 1.00). Of the TAF or TDF‐treated mothers, 25.64% versus 16.98% experienced ALT > 2X ULN, and 11.54% versus 1.89% received extended antiviral treatment. Our model revealed four distinct ALT patterns: stable ALT (87.2%), moderate (8.0%) or marked (2.4%) postpartum flares, or prepartum elevations (2.4%). Conclusions: TAF effectively reduces mother‐to‐child HBV transmission, but prophylaxis failure still occurred in few cases. Postpartum ALT flares are common in women receiving TAF or TDF during pregnancy. Approximately 12.8% of mothers may require extended postpartum antiviral treatment. Clinical trial number: NCT03695029 (ClinicalTrials.gov).
- Subjects
HEPATITIS B virus; TENOFOVIR; INFANTS; PREGNANCY; PREGNANT women
- Publication
Liver International, 2024, Vol 44, Issue 6, p1422
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.15873